Immunohistochemical profile and clinical-pathological variables in breast cancer

被引:3
|
作者
Duarte Cintra, Jane Rocha [1 ]
Bustamante Teixeira, Maria Teresa
Diniz, Roberta Wolp
Goncalves Junior, Homero
Florentino, Thiago Marinho
de Freitas, Guilherme Fialho
Mota Oliveira, Luiz Raphael
dos Reis Neves, Mariana Teodoro
Pereira, Talita
Guerra, Maximiliano Ribeiro
机构
[1] Hosp 9 Julho, Inst Oncol, BR-36010510 Juiz De Fora, MG, Brazil
来源
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA | 2012年 / 58卷 / 02期
关键词
Progesterone receptors; erbB2; receptor; breast neoplasias; immunohistochemistry; estrogen receptors; Ki-67; antigen; ADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; SUBTYPES; TRASTUZUMAB; EXPRESSION; PROGNOSIS; PATTERNS; SURVIVAL; THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immunohistochemical profile and clinical-pathological variables in breast cancer Objective: To describe the main characteristics of women with breast cancer, according to the immunohistochemical profile. Methods: The population comprised a hospital cohort, consisting of women diagnosed with breast cancer between 2003 and 2005 (n = 601) and treated at a referral center for cancer care in Juiz de Fora, MG, Brazil. Only 397 women who had complete immunohistochemistry analysis were selected. To define the groups according to the immunohistochemical profile, the assessment of estrogen and progesterone receptors, Ki-67 cell proliferation index, and overexpression of human epidermal growth factor receptor 2 (HER2) was chosen. According to the different phenotypes, five subtypes were defined: luminal A, luminal B HER2 negative, luminal B HERZ positive, triple negative, and HER2 overexpression. Results: Most patients were white (80.7%) and post-menopausal (64.9%), with a mean age of 57.4 years (+/- 13.5). At diagnosis, 57.5% had tumor size >= 2.0 cm, and 41.7% had lymph node involvement. The most common subtypes were luminal B - HER2 negative (41.8%) and triple negative (24.2%). In the luminal A subtype, 72.1% of patients were post-menopausal, while the highest percentage of premenopausal women were observed in the luminal B - HER2 positive and triple negative subtypes (45.2% and 44.2%, respectively). A higher frequency of tumors > 2.0 cm and lymph node involvement was observed in triple negative and HER2 positive subtypes. Conclusion: This study allowed the distribution assessment of the main clinical and pathological characteristics and those related to health services in a cohort of Brazilian women with breast cancer, according to the immunohistochemical tumor subtypes.
引用
收藏
页码:178 / 187
页数:10
相关论文
共 50 条
  • [1] Brain metastases originating in breast cancer: clinical-pathological analysis and immunohistochemical profile
    Sava, Anca
    Costea, Claudia Florida
    Vatavu, Ruxandra
    Grigore, Mihaela
    Turliuc, Mihaela Dana
    Dumitrescu, Gabriela Florenta
    Eva, Lucian
    Motoc, Andrei Gheorghe Marius
    Stan, Cristinel Ionel
    Gavril, Liviu Ciprian
    Scripcariu, Sadiye Ioana
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2021, 62 (02) : 435 - 444
  • [2] Proteasome Functioning in Breast Cancer: Connection with Clinical-Pathological Factors
    Shashova, Elena E.
    Lyupina, Yulia V.
    Glushchenko, Svetlana A.
    Slonimskaya, Elena M.
    Savenkova, Olga V.
    Kulikov, Alexey M.
    Gornostaev, Nikolay G.
    Kondakova, Irina V.
    Sharova, Natalia P.
    PLOS ONE, 2014, 9 (10):
  • [3] Clinical-pathological features and gene profile in colorectal cancer.
    Perazzo, Florencia
    Piaggio, Fernando
    Krupitzki, Hugo
    Garcia, Alejandro
    Avagnina, Alejandra
    Elsner, Boris
    Denninghoff, Valeria
    MEDICINA-BUENOS AIRES, 2013, 73 (05) : 417 - 422
  • [4] Primary pulmonary rabdomyosarcoma: clinical-pathological and immunohistochemical findings
    Corbo, Maria De Lujan
    Enriquez, Lucia
    Rodriguez, Graciela
    Sarancone, Sandra
    Nocito, Ana Lia
    MEDICINA-BUENOS AIRES, 2022, 82 (05) : 781 - 783
  • [5] Assessment of Breast Cancer Immunohistochemical Properties with Demographics and Pathological Features; A Retrospective Study
    Ariabod, Vahid
    Sohooli, Maryam
    Shekouhi, Ramin
    Payan, Kiana
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2021, 14 (11)
  • [6] Adjuvant breast cancer: which clinical and pathological characteristics in 2007?
    Penault-Llorca, F.
    Arnould, L.
    BULLETIN DU CANCER, 2010, 97 (12) : 1421 - 1426
  • [7] Cytosolic levels of TFF1/pS2 in breast cancer:: their relationship with clinical-pathological parameters and their prognostic significance
    Corte, MD
    Tamargo, F
    Alvarez, A
    Rodríguez, JC
    Vázquez, J
    Sánchez, R
    Lamelas, ML
    González, LO
    Allende, MT
    García-Muñiz, JL
    Fueyo, A
    Vizoso, F
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 96 (01) : 63 - 72
  • [8] The SIRT 3 Expression Profile is Associated with Pathological and Clinical Outcomes in Human Breast Cancer Patients
    He, Shaozhong
    He, Chun
    Yuan, Hua
    Xiong, Shizhong
    Xiao, Zhenyu
    Chen, Longhua
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 34 (06) : 2061 - 2069
  • [9] Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer
    Pinto, Antonio E.
    Areia, Filipa
    Pereira, Teresa
    Cardoso, Paula
    Aparicio, Mariana
    Silva, Giovani L.
    Ferreira, Monica C.
    Andre, Saudade
    SPRINGERPLUS, 2013, 2 : 1 - 8
  • [10] The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition
    Horii, Rie
    Honma, Naoko
    Ogiya, Akiko
    Kozuka, Yuji
    Yoshida, Kazuya
    Yoshida, Masayuki
    Horiguchi, Shin-ichiro
    Ito, Yoshinori
    Mukai, Hirofumi
    BREAST CANCER, 2016, 23 (03) : 391 - 399